Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Wölwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J.
Kron A, et al. Among authors: oeser k.
Eur J Cancer. 2024 Aug;207:114158. doi: 10.1016/j.ejca.2024.114158. Epub 2024 Jun 14.
Eur J Cancer. 2024.
PMID: 38941869
Free article.